Phase 2 N=37 Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
Refractory Plasma Cell Myeloma
Primary: Overall Response Rate — 0.35 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations
Parkinson Disease · Motor Disorder
Primary: Maximal Change in UPDRS Part III From Predose to Postdose on Day 1 — -22.0; -12.5; -11.2; -15.2 score on a scale
Phase 2 N=40 DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
Advanced Breast Cancer · HER2-positive Breast Cancer · Brain Metastases
Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants
Phase 2 N=109 Moderate Alcohol Intake Among Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: Glucose — -21.55; 1.92 mg/dL
Phase 2 N=47 A Teleheath tDCS Approach to Decrease Cannabis Use
Cannabis Use Disorder · Multiple Sclerosis
Primary: Change in Kessler Psychological Distress Scale (K10) Score — 6.4; 4.5 score on a scale
Phase 2 N=66 Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Grade 3a Follicular Lymphoma · Recurrent Follicular Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide When Given With Obinutuzumab Defined as the Highest Dose Level Have Been Treated With Less Than 2 Instances of Dose Limiting…
Phase 2 N=76 Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
Venous Thromboembolism
Primary: Apixaban vs. Enoxaparin - Number of Participants With Bleeding Events — 1; 1 Participants
Phase 2 N=796 A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
Measles; Mumps; Rubella; Chickenpox · Measles
Primary: GMC of Anti-measles Antibodies at Day 43 — 801; 788; 728; 682 mIU/mL
Phase 2 N=20 Methylphenidate for Ptsd and Stroke Veterans
PTSD · Stroke
Primary: Change in Modified Rankin Scale at 12 Weeks — -0.44; -0.50 units on a scale — p=0.896
Phase 2 N=60 Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: MATRICS Consensus Cognitive Battery (MCCB) — 41.8; 39.67 units on a scale
Phase 2 N=281 A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Cancer · Melanoma
Primary: Number of Participants Experiencing Adverse Events (AEs) - Part 1 — 16; 14; 18; 12 Participants
Phase 2 N=93 Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Neuroendocrine Tumor · Anaplastic Thyroid Cancer · Adenocarcinoma
Primary: Objective Response Rate (ORR) — 0; 2; 2; 2 Participants
Phase 2 N=94 Treatment and Natural History Study of Lymphomatoid Granulomatosis
Lymphomatoid Granulomatosis · Granulomatosis, Lymphomatoid · Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants
Phase 2 N=6 Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With a Toxicity — 6; 7; 24 Percentage of participants
Phase 2 N=97 Low-dose Atropine for the Prevention of Myopia Progression in Danish Children
Myopia
Primary: Axial Length at 36 Months — 25.28; 25.25; 25.33 mm